Enrollment

REBETOL®
(ribavirin)
CRIXIVAN®
(indinavir sulfate)
ISENTRESS®
(raltegravir)
GARDASIL®
[Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine]
GARDASIL®9
[human papillomavirus 9-valent vaccine, recombinant]
JANUVIA®
(sitagliptin phosphate)
JANUMET®
(sitagliptin/metformin HCl)
MAXALT®
(rizatriptan benzoate)
SINGULAIR®
(montelukast sodium)
VARICELLA ZOSTER VIRUS-CONTAINING VACCINES


 

Please note that the Pregnancy Registry for REBETOL (Ribavirin Pregnancy Registry) is now CLOSED to new enrollment.

Enrollment was discontinued on November 13, 2020.

Merck wishes to convey its gratitude to the women and health care providers who reported exposure to ribavirin during pregnancy. Their contributions allowed the ongoing surveillance of this product to monitor and describe its safety profile.

Healthcare providers are encouraged to report any exposures to REBETOL during pregnancy. For questions related to exposure to REBETOL during pregnancy or to report new cases of exposure to REBETOL during pregnancy, please contact Merck's National Service Center at 1-877-888-4231.

 


CRIXIVAN  |  GARDASIL  |  GARDASIL 9  |  ISENTRESS  |  JANUVIA  |  JANUMET  |  MAXALT  |  PROQUAD  |  REBETOL  |  SINGULAIR  |  VARIVAX  |  ZOSTAVAX  | 
Enrollment  |  Home  |  Privacy Policy

Copyright 2012 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.

 

 

 

Filemaxalt.html
New Form Import Edit Upload Submit